Summary
This narrative review examines how traditional Chinese medicine modulates immune homeostasis through alterations in the gut microbiota and their metabolic outputs. The authors synthesise evidence that TCM interventions promote beneficial microbial metabolites, suppress harmful ones, and enhance phytochemical biotransformation, with downstream activation of key immune signaling pathways including GPCRs, aryl hydrocarbon receptors, and epigenetic regulators. The review proposes this microbiota–metabolite–immunity axis as a mechanistic framework for understanding TCM's therapeutic effects in inflammatory bowel disease, cancer, metabolic inflammation, and autoimmune diseases.
Regional applicability
The review is mechanistic and not geographically specific, synthesising published evidence on TCM and human immune function. Its applicability to United Kingdom clinical practice depends on the strength of underlying evidence and regulatory status of specific TCM preparations in UK healthcare, which the review does not directly address.
Key measures
Gut microbiota composition, microbial metabolite production (short-chain fatty acids, secondary bile acids, tryptophan metabolites, etc.), immune signaling pathway activation (GPCRs, AhR, FXR, TGR5), mucosal immunity, immune cell differentiation, inflammatory markers, immune homeostasis.
Outcomes reported
The review synthesises mechanisms by which TCM reshapes the gut microbial metabolome to modulate host immune responses and immune homeostasis. It explores the therapeutic role of the TCM–gut microbiota–microbial metabolites axis in inflammatory bowel disease, cancer, metabolic inflammation, autoimmune diseases, and other immune-mediated conditions.
Topic tags
Dig deeper with Pulse AI.
Ask about this record, its theme or its relevance to UK farming and policy. Pulse AI uses selected catalogue evidence and cites the sources it draws on.